Floatz Rating
B63/100
Confidence
Indicative
Sponsor
H. Lundbeck A/S
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05014919CT.gov Vortioxetine to Prevent Return of Symptoms in Children With Depression | — | Terminated | — | — | — |
NCT04301492CT.gov Tolerability, Safety and Efficacy of Vortioxetine | — | Unknown | — | — | — |
NCT02969876CT.gov Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vortioxetine (this asset) | H. Lundbeck A/S | Approved | B · 63 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Saredutant | Sanofi | P3 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| Paroxetine | Brigham and Women's Hospital | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Vortioxetine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Major Depressive Disorder | — | P4 | BBB · 75 |
| Bipolar Depression | — | P4 | BB · 69 |
| Anxiety Disorder | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vortioxetine in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vortioxetine-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →